Dramatic increases in the prevalence of multidrug-resistant bacteria have put the spotlight on the lack of new antibacterials coming through the pipeline. How might regulatory guidance for clinical trials of antibacterials help tackle this shortfall?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Opar, A. Bad bugs need more drugs. Nat Rev Drug Discov 6, 943–944 (2007). https://doi.org/10.1038/nrd2477
Issue Date:
DOI: https://doi.org/10.1038/nrd2477
This article is cited by
-
Antimicrobial Peptides as Potential Therapeutic Agents: A Review
International Journal of Peptide Research and Therapeutics (2021)
-
Rational modification of a dendrimeric peptide with antimicrobial activity: consequences on membrane-binding and biological properties
Amino Acids (2016)
-
The Host Defence Peptide LL-37 is Susceptible to Proteolytic Degradation by Wound Fluid Isolated from Foot Ulcers of Diabetic Patients
International Journal of Peptide Research and Therapeutics (2014)
-
Metabolism of small antimicrobial β2,2-amino acid derivatives by murine liver microsomes
European Journal of Drug Metabolism and Pharmacokinetics (2012)